AU5348301A - Naphthalimide compositions and uses thereof - Google Patents
Naphthalimide compositions and uses thereofInfo
- Publication number
- AU5348301A AU5348301A AU5348301A AU5348301A AU5348301A AU 5348301 A AU5348301 A AU 5348301A AU 5348301 A AU5348301 A AU 5348301A AU 5348301 A AU5348301 A AU 5348301A AU 5348301 A AU5348301 A AU 5348301A
- Authority
- AU
- Australia
- Prior art keywords
- naphthalimide
- agents
- compositions
- host
- proliferative disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000001028 anti-proliverative effect Effects 0.000 abstract 3
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 229960004701 amonafide Drugs 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000138 intercalating agent Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002212 purine nucleoside Substances 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19710300P | 2000-04-12 | 2000-04-12 | |
| PCT/US2001/012169 WO2001078705A2 (en) | 2000-04-12 | 2001-04-12 | Compositions containing a naphthalmide and an antiproliferative agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5348301A true AU5348301A (en) | 2001-10-30 |
Family
ID=22728064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU5348301A Withdrawn AU5348301A (en) | 2000-04-12 | 2001-04-12 | Naphthalimide compositions and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6630173B2 (enExample) |
| EP (1) | EP1274458B1 (enExample) |
| JP (1) | JP2003530431A (enExample) |
| AT (1) | ATE305312T1 (enExample) |
| AU (1) | AU5348301A (enExample) |
| CA (1) | CA2404278C (enExample) |
| DE (1) | DE60113666T2 (enExample) |
| ES (1) | ES2248312T3 (enExample) |
| HK (1) | HK1052874B (enExample) |
| WO (1) | WO2001078705A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE330611T1 (de) * | 2000-03-15 | 2006-07-15 | Chemgenex Pharmaceuticals Inc | Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung |
| US7135481B2 (en) * | 2000-04-12 | 2006-11-14 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US20060211648A1 (en) * | 2000-04-12 | 2006-09-21 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| DE60113666T2 (de) * | 2000-04-12 | 2006-06-14 | Chemgenex Pharmaceuticals Inc | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten |
| US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| US6693198B2 (en) * | 2002-04-22 | 2004-02-17 | Xanthus Life Sciences, Inc. | Amonafide salts |
| US20050239816A1 (en) * | 2002-04-22 | 2005-10-27 | Xanthus Life Sciences, Inc. | Amonafide salts |
| CA2483340A1 (en) * | 2002-04-24 | 2003-11-06 | Research Development Foundation | Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents |
| EP2305257A1 (en) * | 2002-07-08 | 2011-04-06 | ChemGenex Pharmaceuticals, Inc. | Amonafide salts and compositions comprising same |
| CA2492456A1 (en) * | 2002-07-17 | 2004-01-29 | Dennis M. Brown | Formulations and methods of administration of cephalotaxines, including homoharringtonine |
| WO2004009030A2 (en) * | 2002-07-22 | 2004-01-29 | Chemgenex Pharmaceuticals Limited | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| JP2007525214A (ja) * | 2004-01-30 | 2007-09-06 | ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド | Ｎ−アセチルトランスフェラーゼ遺伝子型解析によって投与するナフタルイミド |
| EP1765341A4 (en) * | 2004-06-04 | 2010-04-14 | Chemgenex Pharmaceuticals Inc | PROCESS FOR TREATING PROLIFERATIVE CELL DISEASE USING NAPHTHALIMIDE AND PARP-1 INHIBITORS |
| CA2597323A1 (en) * | 2005-02-10 | 2006-08-17 | Chemgenex Pharmaceuticals, Inc. | Medical devices |
| AU2008240044B2 (en) * | 2007-04-13 | 2013-09-12 | Teva Pharamceuticals International Gmbh | Oral cephalotaxine dosage forms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183821A (en) * | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| FR2673944B1 (fr) * | 1991-03-13 | 1995-03-10 | Sanofi Elf | Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| EA200000087A1 (ru) * | 1997-07-01 | 2000-08-28 | Атеродженикс, Инк. | Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта |
| ATE330611T1 (de) * | 2000-03-15 | 2006-07-15 | Chemgenex Pharmaceuticals Inc | Cephalotaxinalkaloid enthaltende kombinationspräparate und deren verwendung |
| JP2003531138A (ja) * | 2000-03-21 | 2003-10-21 | アセロジエニクス・インコーポレイテツド | 生物学的疾患の治療のためのｎ−置換ジチオカルバメート |
| DE60113666T2 (de) * | 2000-04-12 | 2006-06-14 | Chemgenex Pharmaceuticals Inc | Zusammensetzungen welche ein naphthalmid und ein antiproliferatives mittel enthalten |
-
2001
- 2001-04-12 DE DE60113666T patent/DE60113666T2/de not_active Expired - Lifetime
- 2001-04-12 AT AT01926985T patent/ATE305312T1/de not_active IP Right Cessation
- 2001-04-12 EP EP01926985A patent/EP1274458B1/en not_active Expired - Lifetime
- 2001-04-12 AU AU5348301A patent/AU5348301A/xx not_active Withdrawn
- 2001-04-12 HK HK03105124.5A patent/HK1052874B/en not_active IP Right Cessation
- 2001-04-12 ES ES01926985T patent/ES2248312T3/es not_active Expired - Lifetime
- 2001-04-12 US US09/834,177 patent/US6630173B2/en not_active Expired - Fee Related
- 2001-04-12 CA CA2404278A patent/CA2404278C/en not_active Expired - Fee Related
- 2001-04-12 JP JP2001576006A patent/JP2003530431A/ja not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012169 patent/WO2001078705A2/en not_active Ceased
-
2003
- 2003-07-31 US US10/631,106 patent/US20040047918A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1052874B (en) | 2006-05-04 |
| CA2404278C (en) | 2010-03-23 |
| US6630173B2 (en) | 2003-10-07 |
| DE60113666D1 (de) | 2005-11-03 |
| CA2404278A1 (en) | 2001-10-25 |
| WO2001078705A2 (en) | 2001-10-25 |
| HK1052874A1 (en) | 2003-10-03 |
| US20020025916A1 (en) | 2002-02-28 |
| EP1274458A2 (en) | 2003-01-15 |
| US20040047918A1 (en) | 2004-03-11 |
| ATE305312T1 (de) | 2005-10-15 |
| EP1274458B1 (en) | 2005-09-28 |
| WO2001078705A3 (en) | 2002-06-20 |
| JP2003530431A (ja) | 2003-10-14 |
| DE60113666T2 (de) | 2006-06-14 |
| ES2248312T3 (es) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU5348301A (en) | Naphthalimide compositions and uses thereof | |
| AU4580301A (en) | Cephalotaxine alkaloid compositions and uses thereof | |
| AU7878301A (en) | Method of amplifying nucleic acid | |
| ZA200202479B (en) | Heterocyclic sodium/proton exchange inhibitors and method. | |
| CA2400554A1 (en) | Pyrimidine-4-one derivatives as ldl-pla2 inhibitors | |
| ATE425165T1 (de) | Verfahren zur zubereitung von inhibitoren des nukleosid-metabolismus | |
| HUP0302332A3 (en) | Gene detection method for improving the likelihood of an effective response to an erbb antagoist cancer therapy | |
| IL150641A0 (en) | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | |
| UA103873C2 (ru) | Гетероарильные производные мочевины как ингибиторы р38 и их применение | |
| BR0109577A (pt) | Composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para tratar cânceres em um animal de sangue quente | |
| SI1546174T1 (sl) | Metode in sestavki za rna interferenco | |
| PT1075477E (pt) | Novos n-oxidos de benzonaftiridina | |
| IL157694A0 (en) | Method of determining dihydropyrimidine dehydrogenase gene expression | |
| MY129445A (en) | Compositions for treating inflammatory response | |
| WO2001091741A3 (en) | Compositions containing hexitol and an antiproliferative agent | |
| ATE411815T1 (de) | Methylierte immunstimulierende oligodeoxynukleotide und verfahren zu deren verwendung | |
| EP1583839A3 (en) | METHODS OF CAPTURING, DETECTING AND QUANTIFYING RNA:DNA HYBRIDS AND A MODIFIED RNase H USEFUL THEREIN | |
| WO2000061594A3 (de) | Nucleosid-derivate mit photolabilen schutzgruppen | |
| AU2003260945A1 (en) | Methods of use for thermostable rna ligases | |
| AU2003215161A1 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| WO2007095639A3 (en) | Napht alimide compositions and uses thereof | |
| WO2001091740A3 (en) | Compositions containing naphthaquinone and an antiproliferative agent | |
| AU2003213057A8 (en) | Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid | |
| HUP0300183A3 (en) | Substituted purine derivatives as inhibitors of cell adhesion | |
| NO994382D0 (no) | Metode for bestemmelse av metall i slagg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |